BioAtla (NASDAQ:BCAB) Now Covered by Analysts at JMP Securities

JMP Securities initiated coverage on shares of BioAtla (NASDAQ:BCABGet Rating) in a report published on Thursday, Marketbeat reports. The firm issued an outperform rating and a $17.00 price target on the stock.

Separately, HC Wainwright reduced their price target on shares of BioAtla from $25.00 to $20.00 and set a buy rating on the stock in a research report on Wednesday, August 10th.

BioAtla Stock Down 4.6 %

Shares of BioAtla stock opened at $8.55 on Thursday. BioAtla has a twelve month low of $2.01 and a twelve month high of $38.31. The business has a 50-day moving average price of $6.48 and a 200-day moving average price of $4.70. The firm has a market cap of $319.89 million, a price-to-earnings ratio of -3.13 and a beta of -0.12.

BioAtla (NASDAQ:BCABGet Rating) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.07). During the same quarter last year, the firm posted ($0.90) earnings per share. On average, equities analysts expect that BioAtla will post -2.87 EPS for the current fiscal year.

Insider Buying and Selling at BioAtla

In related news, CEO Jay M. Phd Short bought 26,350 shares of the business’s stock in a transaction dated Friday, August 12th. The shares were purchased at an average price of $7.84 per share, with a total value of $206,584.00. Following the transaction, the chief executive officer now owns 1,396,556 shares in the company, valued at approximately $10,948,999.04. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Jay M. Phd Short bought 26,350 shares of the company’s stock in a transaction on Friday, August 12th. The shares were acquired at an average cost of $7.84 per share, for a total transaction of $206,584.00. Following the purchase, the chief executive officer now directly owns 1,396,556 shares of the company’s stock, valued at $10,948,999.04. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jay M. Phd Short acquired 29,082 shares of BioAtla stock in a transaction on Tuesday, June 21st. The shares were purchased at an average price of $2.79 per share, for a total transaction of $81,138.78. Following the completion of the acquisition, the chief executive officer now directly owns 1,335,674 shares in the company, valued at $3,726,530.46. The disclosure for this purchase can be found here. Insiders have purchased a total of 57,432 shares of company stock worth $305,423 over the last ninety days. Company insiders own 14.80% of the company’s stock.

Hedge Funds Weigh In On BioAtla

Hedge funds and other institutional investors have recently modified their holdings of the business. Prelude Capital Management LLC purchased a new stake in BioAtla during the second quarter worth $45,000. Formidable Asset Management LLC bought a new position in shares of BioAtla in the 2nd quarter worth $205,000. AQR Capital Management LLC purchased a new stake in shares of BioAtla during the 2nd quarter worth $97,000. PDT Partners LLC boosted its position in BioAtla by 6.7% during the second quarter. PDT Partners LLC now owns 101,862 shares of the company’s stock valued at $290,000 after purchasing an additional 6,439 shares in the last quarter. Finally, Laurion Capital Management LP purchased a new position in BioAtla in the second quarter valued at about $834,000. 69.14% of the stock is currently owned by institutional investors.

BioAtla Company Profile

(Get Rating)

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

Featured Stories

Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.